Related Experiment Videos
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
Abstract:
Overexpression of P-glycoprotein (P-gp) is a potential cause of multidrug resistance (MDR) in tumours. We have previously reported that XR9051 (N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phe nyl)-3-((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-pipera zinylidene)methylbenzamide) is a potent and specific inhibitor of P-gp, which reverses drug resistance in several murine and human MDR cell lines. In this study we have evaluated the in vivo efficacy of this novel modulator in a panel of murine and human tumour models and examined its pharmacokinetic profile. Efficacy studies in mice bearing MDR syngeneic tumours (P388/DX Johnson, MC26) or human tumour xenografts (A2780AD, CH1/DOXr, H69/LX) demonstrated that co-administration of XR9051 significantly potentiated the anti-tumour activity of a range of cytotoxic drugs. This modulatory activity was observed following parenteral and oral co-administration of XR9051. In addition, the combination schedules were well-tolerated. Following intravenous administration in mice, XR9051 is rapidly distributed and accumulates in tumours and other tissues. In addition, the compound is well-absorbed after oral administration. These data suggest that XR9051 has the potential for reversing clinical MDR mediated by P-glycoprotien.
Insights
XR9051, a P-glycoprotein inhibitor, effectively enhances chemotherapy in animal models. This drug reverses multidrug resistance (MDR) and shows promising results for clinical applications in cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Overexpression of P-glycoprotein (P-gp) is a key mechanism driving multidrug resistance (MDR) in tumors.
- XR9051 has been identified as a potent and specific inhibitor of P-gp, demonstrating efficacy in reversing drug resistance in various cell lines.
Purpose of the Study:
- To evaluate the in vivo efficacy of XR9051 in reversing multidrug resistance in murine and human tumor models.
- To examine the pharmacokinetic profile of XR9051 following different administration routes.
Main Methods:
- In vivo efficacy studies were conducted using mice bearing multidrug-resistant syngeneic tumors and human tumor xenografts.
- Pharmacokinetic profiling involved intravenous and oral administration of XR9051 in mice.
Main Results:
- Co-administration of XR9051 significantly enhanced the anti-tumor activity of cytotoxic drugs across multiple tumor models.
- This potentiation was observed with both parenteral and oral administration of XR9051, and combination therapies were well-tolerated.
- XR9051 exhibited rapid distribution and tumor accumulation after intravenous administration and good oral absorption.
Conclusions:
- XR9051 demonstrates significant in vivo efficacy in potentiating anti-cancer drug activity by overcoming P-glycoprotein-mediated multidrug resistance.
- The favorable pharmacokinetic profile and tolerability suggest XR9051's potential for clinical application in treating multidrug-resistant cancers.